Potential deleterious effects of vasopressin in chronic kidney disease and particularly autosomal dominant polycystic kidney disease

Kidney and Blood Pressure Research

Volumn 34, Issue 4, 2011, Pages 235-244

  Meijer, E ^a   Boertien, W E ^a   Zietse, R ^b   Gansevoort, R T ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Albuminuria; Autosomal dominant polycystic kidney disease; Chronic kidney disease; Copeptin; Glomerular filtration rate; Proteinuria; Vasopressin

Indexed keywords

PLACEBO; TOLVAPTAN; VASOPRESSIN; VASOPRESSIN RECEPTOR ANTAGONIST;

CHRONIC KIDNEY DISEASE; CONFERENCE PAPER; DISEASE COURSE; FLUID INTAKE; HUMAN; KIDNEY POLYCYSTIC DISEASE; LOW DRUG DOSE; NONHUMAN; PRIORITY JOURNAL; RENAL PROTECTION;

HUMANS; POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT; RENAL INSUFFICIENCY, CHRONIC; VASOPRESSINS; WATER;

EID: 79959500985     PISSN: 14204096     EISSN: 14230143     Source Type: Journal    
DOI: 10.1159/000326902     Document Type: Conference Paper

References (54)

1. Robertson GL, Athar S: The interaction of blood osmolality and blood volume in regu-lating plasma vasopressin in man. J Clin Endocrinol Metab 1976; 42:613-620.
2. Mutig K, Paliege A, Kahl T, Jons T, Muller-Esterl W, Bachmann S: Vasopressin V2 re-ceptor expression along rat, mouse, and hu-man renal epithelia with focus on TAL. Am J Physiol Renal Physiol 2007; 293:F1166-F1177. (Pubitemid 47583950)
3. Aoyagi T, Izumi Y, Hiroyama M, Matsuzaki T, Yasuoka Y, Sanbe A, Miyazaki H, Fujiwara Y, Nakayama Y, Kohda Y, Yamauchi J, Inoue T, Kawahara K, Saito H, Tomita K, Nonogu-chi H, Tanoue A: Vasopressin regulates the renin-angiotensin- aldosterone system via V1a receptors in macula densa cells. Am J Physiol Renal Physiol 2008; 295:F100-F107.
4. Bankir L: Antidiuretic action of vasopressin: quantitative aspects and interaction between V1a and V2 receptor-mediated effects. Car-diovasc Res 2001; 51: 372-390. (Pubitemid 32718586)
5. Perucca J, Bichet DG, Bardoux P, Bouby N, Bankir L: Sodium excretion in response to vasopressin and selective vasopressin recep-tor antagonists. J Am Soc Nephrol 2008; 19: 1721-1731.
6. Gillies GE, Linton EA, Lowry PJ: Corticotro-pin releasing activity of the new CRF is po-tentiated several times by vasopressin. Nature 1982; 299:355-357. (Pubitemid 12012863)
7. Rivier C, Vale W: Modulation of stress-in-duced ACTH release by corticotropin-re-leasing factor, catecholamines and vasopres-sin. Nature 1983; 305: 325-327. (Pubitemid 13010928)
8. Pedersen NB, Hofmeister MV, Rosenbaek LL, Nielsen J, Fenton RA: Vasopressin induc-es phosphorylation of the thiazide-sensitive sodium chloride cotransporter in the distal convoluted tubule. Kidney Int 2010; 78:160-169.
9. Bankir L, Fernandes S, Bardoux P, Bouby N, Bichet DG: Vasopressin-V2 receptor stimu-lation reduces sodium excretion in healthy humans. J Am Soc Nephrol 2005; 16: 1920-1928. (Pubitemid 41716422)
10. Bankir L, Kriz W: Adaptation of the kidney to protein intake and to urine concentrating activity: similar consequences in health and CRF. Kidney Int 1995; 47:7-24.
11. Bouby N Ahloulay M, Nsegbe E, Dechaux M, Schmitt F, Bankir L: Vasopressin increas-es glomerular filtration rate in conscious rats through its antidiuretic action. J Am Soc Nephrol 1996; 7: 842-851. (Pubitemid 27465977)
12. Bardoux P, Martin H, Ahloulay M, Schmitt F, Bouby N Trinh-Trang-Tan MM, Bankir L: Vasopressin contributes to hyperfiltration, albuminuria, and renal hypertrophy in Diabetes mellitus: study in vasopressin-defi-cient Brattleboro rats. Proc Natl Acad Sci USA 1999; 96:10397-10402. (Pubitemid 29422569)
13. Bankir L, Bichet DG, Bouby N Vasopressin V2 receptors, ENaC, and sodium reabsorp-tion: a risk factor for hypertension? Am J Physiol Renal Physiol 2010; 299:F917-F928.
14. Tahara A, Tsukada J, Tomura Y, Suzuki T, Yatsu T, Shibasaki M: Effect of YM218, a nonpeptide vasopressin V(1A) receptor-se-lective antagonist, on rat mesangial cell hy-perplasia and hypertrophy. Vascul Pharmacol 2007; 46: 463-469. (Pubitemid 46552288)
15. Tahara A, Tsukada J, Tomura Y, Yatsu T, Shi-basaki M: Vasopressin increases type IV col-lagen production through the induction of transforming growth factor-beta secretion in rat mesangial cells. Pharmacol Res 2008; 57: 142-150.
16. Bouby N, Bachmann S, Bichet D, Bankir L: Effect of water intake on the progression of chronic renal failure in the 5/6 nephrecto-mized rat. Am J Physiol 1990; 258:F973-F979. (Pubitemid 20155510)
17. Sugiura T, Yamauchi A, Kitamura H, Mat-suoka Y, Horio M, Imai E, Hori M: High wa-ter intake ameliorates tubulointerstitial in-jury in rats with subtotal nephrectomy: pos-sible role of TGF-beta. Kidney Int 1999; 55: 1800-1810. (Pubitemid 29197967)
18. Bouby N Hassler C, Bankir L: Contribution of vasopressin to progression of chronic re-nal failure: study in Brattleboro rats. Life Sci 1999; 65: 991-1004. (Pubitemid 29410384)
19. Naito A, Hasegawa H, Kurasawa T, Ohtake Y, Matsukawa H, Ezure Y, Koike K, Shigeno-bu K: Histopathological study of kidney ab-normalities in an experimental SIADH rat model and its application to the evaluation of the pharmacologic profile of VP-343, a selec-tive vasopressin V2 receptor antagonist. Biol Pharm Bull 2001; 24:897-901. (Pubitemid 32750314)
20. Fernandes S, Bruneval P, Hagege A, Heudes D, Ghostine S, Bouby N: Chronic V2 vaso-pressin receptor stimulation increases basal blood pressure and exacerbates deoxycorti-costerone acetate-salt hypertension. Endocrinology 2002; 143: 2759-2766. (Pubitemid 34701340)
21. Torres VE: Vasopressin in chronic kidney disease: an elephant in the room? Kidney Int 2009;76:925-928.
22. Okada H, Suzuki H, Kanno Y, Yamamura Y Saruta T: Effects of vasopressin V1 and V2 receptor antagonists on progressive renal failure in rats. Clin Sci (Lond) 1994; 86: 399-404. (Pubitemid 24137312)
23. Okada H, Suzuki H, Kanno Y, Yamamura Y Saruta T: Chronic and selective vasopressin blockade in spontaneously hypertensive rats. Am J Physiol 1994; 267:R1467-R1471.
24. Okada H, Suzuki H, Kanno Y, Saruta T: Effects of novel, nonpeptide vasopressin antag-onists on progressive nephrosclerosis in rats. J Cardiovasc Pharmacol 1995; 25:847-852.
25. Okada H, Suzuki H, Kanno Y, Saruta T: Evidence for the involvement of vasopressin in the pathophysiology of adriamycin-induced nephropathy in rats. Nephron 1996; 72:667-672. (Pubitemid 26098270)
26. Kurihara I, Saito T, Obara K, Shoji Y, Hirai M, Soma J, Sato H, Imai Y Abe K: Effect of a nonpeptide vasopressin V1 antagonist (OPC-21268) on experimental accelerated focal glomerulosclerosis. Nephron 1996; 73: 629-636. (Pubitemid 26258199)
27. Bardoux P, Bruneval P, Heudes D, Bouby N, Bankir L: Diabetes-induced albuminuria: role of antidiuretic hormone as revealed by chronic V2 receptor antagonism in rats. Nephrol Dial Transplant 2003; 18: 1755-1763. (Pubitemid 37098545)
28. Windt WA, Tahara A, Kluppel AC, De Zeeuw D, Henning RH, van Dokkum RP: Early, but not late therapy with a vasopressin V1a-an-tagonist ameliorates the development of re-nal damage after 5/6 nephrectomy. J Renin Angiotensin Aldosterone Syst 2006; 7:217-224. (Pubitemid 46380772)
29. Okada T, Sakaguchi T, Hatamura I, Saji F, Negi S, Otani H, Muragaki Y, Kawachi H, Shigematsu T: Tolvaptan, a selective oral va-sopressin V2 receptor antagonist, amelio-rates podocyte injury in puromycin amino-nucleoside nephrotic rats. Clin Exp Nephrol 2009; 13: 438-446.
30. Perico N, Zoja C, Corna D, Rottoli D, Gas-pari F, Haskell L, Remuzzi G: V1/V2 vaso-pressin receptor antagonism potentiates the renoprotection of renin-angiotensin system inhibition in rats with renal mass reduction. Kidney Int 2009; 76:960-967.
31. Hebert LA, Greene T, Levey A, Falkenhain ME, Klahr S: High urine volume and low urine osmolality are risk factors for faster progression of renal disease. Am J Kidney Dis 2003; 41: 962-971. (Pubitemid 36532130)
32. Bricker NS, Dewey RR, Lubowitz H, Stokes J, Kirkensgaard T: Observations on the con-centrating and diluting mechanisms of the diseased kidney. J Clin Invest 1959; 38: 516-523.
33. Preibisz JJ, Sealey JE, Laragh JH, Cody RJ, Weksler BB: Plasma and platelet vasopressin in essential hypertension and congestive heart failure. Hypertension 1983; 5:I129-I138.
34. Robertson GL, Mahr EA, Athar S, Sinha T: Development and clinical application of a new method for the radioimmunoassay of arginine vasopressin in human plasma. J Clin Invest 1973; 52: 2340-2352.
35. Morgenthaler NG, Struck J, Alonso C, Berg-mann A: Assay for the measurement of co-peptin, a stable peptide derived from the pre-cursor of vasopressin. Clin Chem 2006; 52: 112-119. (Pubitemid 43032474)
36. Morgenthaler NG, Struck J, Jochberger S, Dunser MW: Copeptin: clinical use of a new biomarker. Trends Endocrinol Metab 2008; 19: 43-49. (Pubitemid 351317895)
37. Meijer E, Bakker SJ, Halbesma N, de Jong PE, Struck J, Gansevoort RT: Copeptin, a surro-gate marker of vasopressin, is associated with microalbuminuria in a large population cohort. Kidney Int 2010; 77:29-36.
38. Zerbe RL, Vinicor F, Robertson GL: Plasma vasopressin in uncontrolled diabetes melli-tus. Diabetes 1979; 28:503-508. (Pubitemid 9190908)
39. Enhorning S, Wang TJ, Nilsson PM, Almgren P, Hedblad B, Berglund G, Struck J, Morgen-thaler NG, Bergmann A, Lindholm E, Groop L, Lyssenko V, Orho-Melander M, Newton-Cheh C, Melander O: Plasma copeptin and the risk of diabetes mellitus. Circulation 2010; 121:2102-2108.
40. Maier C, Clodi M, Neuhold S, Resl M, El-henicky M, Prager R, Moertl D, Strunk G, Luger A, Struck J, Pacher R, Hulsmann M: Endothelial markers may link kidney func-tion to cardiovascular events in type 2 diabe-tes. Diabetes Care 2009; 32:1890-1895.
41. Meijer E, Bakker SJ, de Jong PE, Homan van der Heide JJ, van Son WJ, Struck J, Lems SP, Gansevoort RT: Copeptin, a surrogate mark-er of vasopressin, is associated with acceler-ated renal function decline in renal Transplant recipients. Transplantation 2009; 88: 561-567.
42. Bardoux P, Bichet DG, Martin H, Gallois Y, Marre M, Arthus MF, Lonergan M, Ruel N, Bouby N, Bankir L: Vasopressin increases urinary albumin excretion in rats and hu-mans: involvement of V2 receptors and the renin-angiotensin system. Nephrol Dial Transplant 2003; 18: 497-506. (Pubitemid 36305653)
43. Belibi FA, Reif G, Wallace DP, Yamaguchi T, Olsen L, Li H, Helmkamp GM Jr, Grantham JJ: Cyclic AMP promotes growth and secre-tion in human polycystic kidney epithelial cells. Kidney Int 2004; 66: 964-973. (Pubitemid 39120999)
44. Torres VE, Wang X, Qian Q, Somlo S, Harris PC, Gattone VH: Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease. Nat Med 2004; 10: 363-364. (Pubitemid 38508512)
45. Gattone VH, Wang X, Harris PC, Torres VE: Inhibition of renal cystic disease develop-ment and progression by a vasopressin V2 receptor antagonist. Nat Med 2003; 9: 1323-1326. (Pubitemid 37279858)
46. Gabow PA, Kaehny WD, Johnson AM, Duley IT, Manco-Johnson M, Lezotte DC, Schrier RW: The clinical utility of renal concentrat-ing capacity in polycystic kidney disease. Kidney Int 1989; 35: 675-680. (Pubitemid 19051769)
47. Meijer E, Bakker SJ, van der Jagt EJ, Navis G, de Jong PE, Struck J, Gansevoort RT: Copeptin, a surrogate marker of vasopressin, is associated with disease severity in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 2011; 6: 361-368.
48. Tannen RL, Regal EM, Dunn MJ, Schrier RW: Vasopressin-resistant hyposthenuria in advanced chronic renal disease. N Engl J Med 1969; 280:1135-1141.
49. Garcia Nieto VM, Yanes MI, Zamorano MM, Gonzalez MJ, Aros CP, Garin EH: Re-nal concentrating capacity as a marker for glomerular filtration rate. Acta Paediatr 2008; 97:96-99.
50. Perico N, Zoja C, Corna D, Rottoli D, Gas-pari F, Haskell L, Remuzzi G: V1/V2 vaso-pressin receptor antagonism potentiates the renoprotection of renin-angiotensin system inhibition in rats with renal mass reduction. Kidney Int 2009; 76:960-967.
51. Wang X, Gattone V, Harris PC, Torres VE: Effectiveness of vasopressin V2 receptor an-tagonists OPC-31260 and OPC-41061 on polycystic kidney disease development in the PCK rat. J Am Soc Nephrol 2005; 16:846-851. (Pubitemid 41710293)
52. Meijer E, Gansevoort RT, de Jong PE, Wal A, Leonhard WN, de Krey S, Goor H, de Heer E, Born J, Peters DJ: Vasopressin V2 receptor antagonism in autosomal dominant polycys-tic kidney disease: optimal timing and dos-ing of the drug. Nephrol Dial Transplant 2011, E-pub ahead of print.
53. Torres VE, Chapman AB, Grantham JJ, Wat-nick TJ, Ouyang J, Krasa HB, Czerwiec FS: TEMPO 2/4 update: changes in ADPKD to-tal kidney volume and eGFR with 3 years of tolvaptan and after withdrawal. Abstract ASN 2010:F-PO1822.
54. Torres VE, Meijer E, Bae KT, Chapman A, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, Perrone RD, Krasa HB, Ouy-ang J, Czerwiec F: Rationale and design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes) 3-4 study. Am J Kidney Dis 2011, E-pub ahead of print.